Sequence information
Variant position: 57 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 504 The length of the canonical sequence.
Location on the sequence:
LRKANDQSGRCQYTFSVASP
N ESSCPEQSQAMSVIHNLQRD
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LRKANDQSG-----------RCQYT------------------------FSVASPN ESSCPEQSQAMSV--IHNLQ-------------------------------------RD
LRKANDRSG-----------RCQYI----------------
Mouse FRKANDRSG-----------RCQYT----------------
Rat FRKANDRSG-----------RCQYT----------------
Bovine FQKANDRSG-----------RCQYT----------------
Rabbit LRKANDRSG-----------RCQYT----------------
Cat LRKANDRSG-----------RCQYT----------------
Slime mold FNQKNEPEGGKITNYLLEKSRVVFQLKGERNFHIFYQFCRG
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
Chain
33 – 504
Myocilin
Chain
33 – 226
Myocilin, N-terminal fragment
Glycosylation
57 – 57
N-linked (GlcNAc...) asparagine
Literature citations
Characterization of rabbit myocilin: implications for human myocilin glycosylation and signal peptide usage.
Shepard A.R.; Jacobson N.; Sui R.; Steely H.T.; Lotery A.J.; Stone E.M.; Clark A.F.;
BMC Genet. 4:5-5(2003)
Cited for: CHARACTERIZATION OF VARIANT SER-57; GLYCOSYLATION; TISSUE SPECIFICITY; SUBCELLULAR LOCATION;
Myocilin analysis by DHPLC in French POAG patients: increased prevalence of Q368X mutation.
Melki R.; Belmouden A.; Brezin A.; Garchon H.-J.;
Hum. Mutat. 22:179-179(2003)
Cited for: VARIANTS GLC1A ARG-367; ILE-438; LYS-480 AND PHE-499; VARIANTS SER-57; LYS-76 AND ARG-398;
Disclaimer:
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.